Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed signals: a slight revenue beat and strong cash position, but EPS missed expectations. The Q&A highlighted management's evasiveness on safety data and efficacy thresholds, raising concerns. Although share repurchase authorization remains, the lack of strong positive catalysts and cautious market conditions suggest a neutral stock price movement. The company's market cap indicates moderate volatility, so a 2% swing is plausible.
Reported EPS $0.13 EPS, down from expectations of $0.28.
Net Sales from Proprietary Product Portfolio $244.5 million, reflecting a 5% year-over-year growth, primarily driven by LYBALVI.
VIVITROL Net Sales $101 million, primarily driven by the alcohol dependence indication, which accounts for approximately 75% of VIVITROL volume.
ARISTADA Net Sales $73.5 million, with expectations for 2025 in the range of $335 million to $355 million.
LYBALVI Net Sales $70 million, representing a 23% year-over-year growth, driven by underlying TRx growth of 22%.
Gross-to-Net Adjustments Approximately 31% in Q1, expected to remain consistent in the low-to-mid 30% range for the remainder of 2025.
Total Revenues $306.5 million, slightly ahead of expectations, driven by proprietary product portfolio growth of 5% year-over-year.
Manufacturing and Royalty Revenues $62 million for Q1, including $27.8 million from VUMERITY, $17.7 million from long-acting INVEGA products, and approximately $9 million from RISPERDAL CONSTA.
Cost of Goods Sold $49.2 million, down from $58.6 million for Q1 last year, primarily reflecting efficiencies after the sale of the Athlone-based manufacturing business.
R&D Expenses $71.8 million, up from $67.6 million for Q1 last year, due to focused investments in neuroscience development programs.
SG&A Expenses $171.7 million, down from $179.7 million for Q1 last year, reflecting a mix of promotional activities.
GAAP Net Income $22.5 million.
EBITDA $22.8 million.
Adjusted EBITDA $45.6 million.
Cash and Total Investments $916.2 million at the end of Q1.
Remaining Share Repurchase Authorization $200 million.
LYBALVI Net Sales: Net sales grew 23% year-over-year to $70 million, driven by underlying TRx growth of 22.
ARISTADA Net Sales: Net sales were $73.5 million, with expectations for 2025 in the range of $335 million to $355 million.
VIVITROL Net Sales: Net sales were $101 million, primarily driven by the alcohol dependence indication.
Psychiatry Sales Force Expansion: Completed the expansion of the psychiatry sales force, now fully deployed to maintain competitive share of voice for LYBALVI and reaccelerate growth for ARISTADA.
Cost of Goods Sold: Cost of goods sold were $49.2 million, down from $58.6 million last year, reflecting operational efficiencies.
Cash Position: Ended the first quarter with $916.2 million in cash and total investments.
Orexin 2 Development: ALKS 2680 Phase 2 program is advancing with strong momentum, with top-line results expected early in Q3.
Project Saturn: Initiating clinical work for new molecules targeting a broad range of disorders, with two additional orexin 2 receptor agonists expected to enter first-in-human studies this year.
Earnings Expectations: Alkermes missed earnings expectations with reported EPS of $0.13 compared to the expected $0.28.
Regulatory Issues: The company is closely monitoring Medicaid changes and FDA regulations, which could impact their business.
Supply Chain Challenges: While Alkermes sources most of its manufacturing domestically, it imports a small amount of active pharmaceutical ingredients (APIs) from abroad, representing less than 5% of costs. They maintain significant safety stock of APIs to mitigate supply chain disruptions.
Macroeconomic Conditions: The macroeconomic environment is described as dynamic and rapidly evolving, which poses potential risks to business operations.
Competitive Pressures: Alkermes is focused on maintaining a competitive share of voice for its products, particularly LYBALVI and ARISTADA, amid a growing psychiatry market.
Financial Position: Despite a strong financial position with over $900 million in cash, the company acknowledges the need to adapt quickly to changing economic conditions.
Strategic Initiatives: Alkermes is focused on maximizing the potential of its commercial products: LYBALVI, ARISTADA, and VIVITROL, with strategic investments to drive awareness and uptake.
R&D Developments: The ALKS 2680 Phase 2 program is advancing with strong momentum, with top-line results expected early in Q3 2025 for the NT1 study and mid-year enrollment completion for the NT2 study.
Project Saturn: Initiative to advance new molecules for a broad range of disorders, with plans to start clinical work this year.
Revenue Expectations: For 2025, VIVITROL net sales are expected in the range of $440 million to $460 million, ARISTADA net sales in the range of $335 million to $355 million, and LYBALVI net sales in the range of $320 million to $340 million.
Q2 Guidance: Q2 net sales from the proprietary product portfolio are expected in the range of $260 million to $280 million.
Financial Position: Alkermes ended Q1 with $916.2 million in cash and investments, with a focus on driving profitability and maintaining a strong balance sheet.
R&D Expenses: R&D expenses are expected to increase modestly in Q2 and remain consistent for the remainder of the year.
SG&A Expenses: SG&A expenses in Q2 are expected to remain consistent with Q1 levels, with a modest step down in the second half of the year.
Share Repurchase Authorization: Alkermes has $200 million of remaining share repurchase authorization, and may opportunistically repurchase shares depending on market conditions and capital needs.
The earnings call summary indicates strong financial performance, with expectations of record revenues and profitability. Product development shows promise with ongoing trials and potential market expansion. Market strategy focuses on expanding orexin portfolio, which is promising. Expenses and financial health appear stable, and the shareholder return plan is not explicitly negative. Q&A insights reveal optimism for product growth and strategic developments, though some guidance was withheld. Overall, the sentiment is positive, suggesting a potential stock price increase in the short term.
The earnings call reveals strong financial performance with revenue growth attributed to high demand, a solid cash position, and strategic advancements in product development. While management avoided certain specifics, the overall sentiment is positive due to the promising pipeline developments, expanded sales force, and strategic initiatives. The market cap suggests a moderate reaction, leading to an anticipated stock price increase of 2% to 8% over the next two weeks.
The earnings call revealed mixed signals: a slight revenue beat and strong cash position, but EPS missed expectations. The Q&A highlighted management's evasiveness on safety data and efficacy thresholds, raising concerns. Although share repurchase authorization remains, the lack of strong positive catalysts and cautious market conditions suggest a neutral stock price movement. The company's market cap indicates moderate volatility, so a 2% swing is plausible.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
